The Ahmedabad-based Zydus Cadila Healthcare has bagged the global marketing rights of Vaxirab, an anti-rabies vaccine, from Swiss company Berna Biotech.
The drug will also be manufactured by Zydus Cadila Healthcare at a Rs 16 crore plant to be set up by the company on the outskirts of Ahmedabad.
The vaccine, which is currently licensed in 30 countries in Europe, south-east Asia and Latin America, was earlier being manufactured and marketed by Berna Biotech globally.
Berna Biotech, which has handed over Vaxirab to the Rs 1,100 crore Zydus Cadila under a technology transfer agreement, will also provide technical assistance to Zydus for setting up the plant.
